The global muscle health sector is undergoing a significant recalibration in 2025, as emerging research, regulatory updates, and consumer behavior converge on a single, complex biomarker: muscle mass. No longer confined to bodybuilding supplements or sports nutrition, muscle mass is now a central metric in longevity medicine, metabolic disease management, and even oncology supportive care. This week’s developments reveal a decisive move away from generic “high-protein” messaging toward precision timing, digital biomarkers, and clinical integration.

Industry Dynamic 1: The Collagen-Specific Protein Debate Intensifies

At the recent International Society of Sports Nutrition (ISSN) annual meeting in Orlando, a contentious panel on “Protein Quality for Lean Mass Preservation” highlighted a growing rift between dairy-based and plant-based factions. While whey protein remains the gold standard for acute muscle protein synthesis (MPS), new head-to-head trials presented at the conference showed that a blended pea-rice-collagen matrix (with a leucine content adjusted to 3.2g per serving) produced comparable 24-hour myofibrillar fractional synthetic rates in older adults (mean age 68) when paired with resistance training. However, the more striking finding was the role of type I collagen peptides—not for MPS directly, but for reducing perimuscular adipose tissue infiltration, a fat depot that impairs muscle quality independent of total mass.

Dr. Elena Vasquez, a geriatric sarcopenia researcher from the University of Barcelona, commented: “We are moving past the ‘how many grams’ question. The industry now recognizes that muscle mass quality—meaning the ratio of contractile protein to intramuscular fat and fibrosis—is more predictive of physical function than total cross-sectional area. Collagen’s role in tendon remodeling and extracellular matrix turnover is shifting from a niche ingredient to a strategic component in muscle health formulations.”

Trend Analysis: The Rise of “Muscle Mass Maintenance” in GLP-1 Era

The most disruptive market force this quarter is the intersection of muscle mass and incretin-based weight loss therapies. As GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) continue to expand their indications, a well-documented side effect—rapid lean tissue loss—has triggered a surge in “muscle-sparing” protocols. Industry data from a proprietary consumer tracker (N = 12,000 U.S. adults) shows that 41% of current GLP-1 users are now actively purchasing a dedicated muscle mass support supplement, up from 17% in Q1 2024.

This has prompted major ingredient suppliers to re-engineer their portfolios. One notable announcement came from FrieslandCampina Ingredients, which launched a new “GLP-1 Companion” line featuring a slow-digesting casein micelle and a patented HMB (β-hydroxy-β-methylbutyrate) calcium complex. The company claims that this combination, when taken at bedtime, attenuates the nocturnal decline in MPS that is exacerbated by calorie restriction and reduced appetite. Meanwhile, the Council for Responsible Nutrition (CRN) has released preliminary guidance urging manufacturers to avoid “miracle mass” claims and instead focus on measurable outcomes like grip strength and chair-stand tests, aligning with FDA’s draft guidance on sarcopenia drug development.

Regulatory & Clinical Milestone: Sarcopenia Gets a Global ICD-11 Push

In a landmark move, the World Health Organization’s 2025 revision of the International Classification of Diseases (ICD-11) has formally added a distinct code for “primary sarcopenia” (FB32.0) with severity grading based on appendicular lean mass index (ALMI) and handgrip strength. This coding change, effective January 1, has immediate reimbursement implications. Several European national health systems (including Germany and France) have announced pilot programs to cover dual-energy X-ray absorptiometry (DXA) scans for adults over 60 with a history of falls.

The clinical community is responding with new diagnostic algorithms. A consortium of 14 academic medical centers published a consensus statement inThe Lancet Healthy Longevitythis week, recommending that bioelectrical impedance analysis (BIA) be replaced by a two-step approach: first, a low-cost calf circumference measurement (as a screening tool), then a confirmatory DXA or CT-based L3 vertebral muscle index for high-risk patients. Notably, the statement also criticizes the over-reliance on body mass index (BMI), citing that “normal-weight obesity” (sarcopenic obesity) remains undiagnosed in 23% of primary care visits.

Expert Perspective: Dr. Marcus Chen on AI and Muscle Mass Assessment

We spoke with Dr. Marcus Chen, chief medical officer at the digital health startup MuscleMetric, which recently secured $40 million in Series B funding for its computer-vision-based sarcopenia screening app. Dr. Chen argues that the future of muscle mass monitoring lies not in lab visits but in passive, smartphone-integrated analysis.

“We have validated a convolutional neural network that estimates thigh muscle cross-sectional area from a standard smartphone video of a sit-to-stand test, with a correlation coefficient of 0.89 against DXA,” Dr. Chen explained. “The industry is finally understanding that muscle mass is not a static number but a dynamic vital sign. We are building integrations with electronic health records so that a patient’s monthly muscle mass trajectory can be visualized alongside blood pressure and glucose. This is the shift from reactive treatment to proactive maintenance.”

However, Dr. Chen also cautioned against over-digitization. “The risk is that consumers obsess over a single metric and neglect neuromuscular adaptation. Muscle mass without neural drive is like a car with a powerful engine but no transmission. We are advising our partners to pair mass estimates with functional tests—like walking speed and one-repetition maximum—to provide a holistic picture.”

Market Consolidation and Ingredient Innovation

The commercial landscape is seeing rapid consolidation. This week, Nestlé Health Science announced the acquisition of a minority stake in the biotech firm MyoSynth, which specializes in synthetic myostatin inhibitors derived from follistatin-like proteins. While myostatin inhibition has historically been fraught with safety concerns (cardiomegaly in animal models), MyoSynth’s oral peptide delivery system claims to achieve local muscle-specific modulation without systemic off-target effects. Phase 2 trials are expected to begin in Q3 2025, targeting cancer cachexia patients.

In the ingredient space, a new prebiotic fiber blend (galacto-oligosaccharides + resistant starch) is gaining traction, not for direct anabolic effects but for its role in modulating the gut-muscle axis. A randomized controlled trial published inNutrientsthis week showed that 12 weeks of supplementation increased serum short-chain fatty acids (particularly butyrate) and was associated with a 4.2% greater increase in quadriceps cross-sectional area in resistance-trained women compared to placebo, independent of protein intake. This suggests that muscle mass outcomes may be partially mediated by gut microbial metabolism of dietary fiber.

Outlook: From “Mass” to “Function”

As the industry heads into the second half of 2025, the consensus among analysts is that the term “muscle mass” itself is becoming insufficient. Experts are advocating for a composite “muscle health index” that includes mass, strength, power, and metabolic flexibility. The upcoming 2025 American College of Sports Medicine (ACSM) annual meeting will feature a dedicated symposium titled “Beyond Muscle Mass: New Biomarkers for an Aging Population,” which is expected to set the agenda for the next decade.

For stakeholders—from supplement formulators to clinicians—the key takeaway is clear: the era of generic “gain muscle” marketing is over. The new standard requires evidence of muscle quality, personalized dosing windows, and integration with digital health platforms. As Dr. Vasquez concluded, “We are not just building bigger muscles anymore. We are building more resilient humans.”